The impact of p53 status on cellular sensitivity to antifolate drugs

Clinical Cancer Research

Volumn 7, Issue 7, 2001, Pages 2114-2123

  Lu, X ^a   Errington, J ^a   Curtin, N J ^a   Lunec, J ^a   Newell, D R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST; LOMETREXOL; METHOTREXATE; PEMETREXED; PROTEIN P53; RALTITREXED; SULFORHODAMINE B;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL COUNT; CELL CYCLE; CELL DIVISION; CELL GROWTH; CELL STRAIN; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENOTYPE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LUNG CANCER; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; STRAIN DIFFERENCE;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID ANTAGONISTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; GLUTAMATES; GUANINE; HUMANS; METHOTREXATE; MUTATION; QUINAZOLINES; SENSITIVITY AND SPECIFICITY; TETRAHYDROFOLATES; THIOPHENES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034777846     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Antifolates
2. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study
3. Synthesis of pyrazolo[3,4,-d]pyrimidine analogues of the potent antitumor agent N-{4-[2-(2-amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}- L-glutamic acid (LY231514)
4. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis
5. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors
6. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
7. New antimetabolites in preclinical and clinical development
8. Antifolates in clinical development
9. Folate and antifolate pharmacology
10. Predicting response to cancer chemotherapy: The role of p53
11. p53 and chemosensitivity
12. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
13. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity
14. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity
15. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
16. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage
17. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
18. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells
19. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage
20. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells
21. New colorimetric cytotoxicity assay for anticancer-drug screening
22. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines
23. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines
24. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma
25. Cell cycle effects of antifolate antimetabolites: Implications for cytotoxicity and cytostasis